Lactobacillus acidophilus and bifidobacterium bifidum reduce chronic HCV progression: Thesis Abstract
Nabieh, M., Salem, M., Allam, N., EL-Batae, H. (2021). Lactobacillus acidophilus and bifidobacterium bifidum reduce chronic HCV progression: Thesis Abstract. EKB Journal Management System, 5(0), 33-33. doi: 10.21608/jcbr.2021.63823.1180
Maii Nabieh; Mohamed Labib Salem; Nanis Allam; Hassan EL-Batae. "Lactobacillus acidophilus and bifidobacterium bifidum reduce chronic HCV progression: Thesis Abstract". EKB Journal Management System, 5, 0, 2021, 33-33. doi: 10.21608/jcbr.2021.63823.1180
Nabieh, M., Salem, M., Allam, N., EL-Batae, H. (2021). 'Lactobacillus acidophilus and bifidobacterium bifidum reduce chronic HCV progression: Thesis Abstract', EKB Journal Management System, 5(0), pp. 33-33. doi: 10.21608/jcbr.2021.63823.1180
Nabieh, M., Salem, M., Allam, N., EL-Batae, H. Lactobacillus acidophilus and bifidobacterium bifidum reduce chronic HCV progression: Thesis Abstract. EKB Journal Management System, 2021; 5(0): 33-33. doi: 10.21608/jcbr.2021.63823.1180

Lactobacillus acidophilus and bifidobacterium bifidum reduce chronic HCV progression: Thesis Abstract

Egyptian Journal of Cancer and Biomedical Research
Article 35, Volume 5, Issue 0, May 2021, Page 33-33  XML PDF (183.42 K)
Document Type: Essay Abstract
DOI: 10.21608/jcbr.2021.63823.1180
View on SCiNiTO View on SCiNiTO
Authors
Maii Nabieh email orcid 1; Mohamed Labib Salemorcid 2; Nanis Allam3; Hassan EL-Batae4
1Microbiology Department, Faculty Science, Tanta university, Tanta, Egypt
2Immunology and Biotechnology Division, Department of Zoology, Faculty of Science, Tanta University, Egypt
3Microbiology Department, Faculty of Science, Tanta University, Tanta, Egypt
4Professor of the Liver, Gastrointestinal Tract and Infectious Diseases, Department of Tropical Medicine, Kafr El-Shiekh University, Egypt
Abstract
Thesis Abstract
Background: Hepatitis C virus (HCV) is a major leading cause of pathogenesis of liver disease which was treated with IFN-based therapy and recently with Sovaldi®. There is a challenge to explore new drugs. Probiotics are the most common natural therapeutic that can ameliorate liver dysfunction. Aim: study the antiviral and antibacterial responses of the probiotics in patients with chronic (HCV). Materials and Methods: patients were treated with IFN/ribavirin, or both IFN and probiotics capsule that was containing L. acidophilus and Bifidobacterium spp. and administered as one capsule per day for a month. Blood and urine samples were collected before and after treatment strategies and were processed for quantitative determination of HCV PCR assay, identification of bacteria by VITEK2 system and 16S r RNA gene sequencing, estimation of probiotics antibacterial activity, as well as counts of leukocytes and CD3+ T cells and CD56+ natural killer cells. Results: Treatment of patients with L. acidophilus and Bifidobacteria spp. enhanced the responses of the patients to IFN-α and ribavirin treatment, as shown by the viral titter of HCV PCR assay that clarified the antiviral activity and also the antibacterial activity against the most common bacterial infections in patients with chronic HCV. Additionally, it increased the numbers of CD3+ and CD56+, Conclusions: Treatment with probiotics before IFN-α and ribavirin therapy can act as a supportive supplement with antiviral, positive immune response and antibacterial activities
Keywords
Bifidobacterium befidum; Lactobacillus acidophilus; HCV infection, Probiotics
Statistics
Article View: 519
PDF Download: 150